Why undergoing this examination?

Irinotecan is an analogue of camptothecin, an approved drug for the treatment of advanced colorectal cancer, and also for lung, brain and breast tumors. A genetic variant in the TATA element has been described in the promoter of the UGT1A1 gene, which may produce a decrease in the expression of the UGT1A1 gene, and, therefore, protein synthesis (the enzyme UGT1A1). Decreased levels of the UGT1A1 enzyme may produce accumulation of the active metabolite SN-38, and consequently the adverse effects and toxicity associated with treatment with irinotecan.

What is this exam?

The genetic profile FG – Onco Irinotecan studies the main allelic variants of the UGT1A1 gene with known clinical relevance. The efficacy and toxicity of drugs depends largely on genes and genetic variants among individuals.

For whom is it indicated?

• Patients on pharmacological treatment who wish to customize medication based on their genetic profile
• Patients in whom pharmacological treatments do not show the expected results


Next Generation Sequencing (NGS)


• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Detailed report including, in addition to the type of metabolism of each enzyme, which drugs can generate toxic effects and adverse reactions, as well as dose recommendations.
• Information provided by the analysis allows the selection of the most appropriate drug, and determines the most appropriate dose for each patient.
• Genetic counseling available at no additional cost, according to the needs of each client.

Extra information

DOCUMENTATION – Available on Extranet for clients:
• Informed Consent
• Clinical Questionnaire
• Fasting is not necessary for the test.

Delivery Time
20 working days
Type of Sample
5 mL whole blood in EDTA tube

Subscribe to our newsletter\n

Subscribe to receive news about our exams